Open Access Case Report Article ID: IJVSR-1-103

    Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

    Johanna K Ecke, Luis Del Valle, Amanda Parker Struckhoff, Piotr Waligorski, Krzysztof Reiss and Francesca Peruzzi*

    Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high cholesterol and high triglyceride levels in humans. However, fenofibrate has also been shown to possess anti-proliferative and anti-metastatic properties against several aggressive and highly metastatic tumors in vitro and in small animal models.We report a case of a 6.5-year-old dog diagnosed with a splenic hemangiosarcoma and treated solely with micronized fenofibrate, administered orally once a day following splenectomy. The dog survived for over 26 months (804 days) after initial diagnosis without signs of adverse effects due to fenofibrate treatment

    Keywords: Dog; Fenofibrate; Hemangiosarcoma; Spleen

    Published on: Oct 16, 2015 Pages: 8-10

    Full Text PDF Full Text HTML DOI: 10.17352/ijvsr.000003
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJVSR